Quaternary substituted PDE4 inhibitors I: The synthesis and in vitro evaluation of a novel series of oxindoles

Bioorganic & Medicinal Chemistry Letters
1998.0

Abstract

The following letter presents the synthesis and in vitro evaluation of a novel quaternary substituted series of phosphodiesterase type (IV) (PDE4) inhibitors. The compounds represent conformationally constrained analogues of the Celltech PDE IV inhibitor, CDP 840. Examples with sub-micromolar IC50's for PDE4 inhibition are reported.

DOI： 10.1016/s0960-894x(97)10206-2

Knowledge Graph

Similar Paper

Quaternary substituted PDE4 inhibitors I: The synthesis and in vitro evaluation of a novel series of oxindoles
Bioorganic & Medicinal Chemistry Letters 1998.0
The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I
Bioorganic & Medicinal Chemistry Letters 1998.0
The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I
Bioorganic & Medicinal Chemistry Letters 2000.0
Novel Cyclic Compounds as Potent Phosphodiesterase 4 Inhibitors
Journal of Medicinal Chemistry 1998.0
Novel indolizine compounds as potent inhibitors of phosphodiesterase IV (PDE4): structure–activity relationship
Med. Chem. Commun. 2010.0
Orally active indole N-oxide PDE4 inhibitors
Bioorganic & Medicinal Chemistry Letters 1998.0
Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors
Bioorganic & Medicinal Chemistry Letters 2015.0
Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma
Bioorganic & Medicinal Chemistry Letters 1998.0
Phthalazine PDE4 inhibitors. Part 2: The synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives
Bioorganic & Medicinal Chemistry Letters 2001.0
Rhodanine derivatives as novel inhibitors of PDE4
Bioorganic & Medicinal Chemistry Letters 2008.0